No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 24 of the 40 quarters in the window, leaving 16 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T20:52:46.146Z. Latest historical point 2023-05-15. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for ProMIS Neurosciences, Inc. (PMN) stock was $9.21 as of Oct 6, 2026, 4:00 PM EDT, down 1.71% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -24.6% · 3-year avg -41.3%/yr · 5-year avg -47.0%/yr
ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA).
Biotechnology · Toronto, ON
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-1.27
Revenue Est.
N/A
Last Quarter Results
EPS
$-1.28
vs Estimate
$-1.38
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1PMN | $82.59M | $9.21 | -1.71% | -24.64% | -47.05% | -22.51% | N/A |
| 2TELO | $82.53M | $1.20 | -0.83% | -13.51% | N/A | N/A | vs PMN |
| 3CRDF | $82.47M | $1.07 | -6.14% | -47.78% | -30.36% | -43.20% | vs PMN |
| 4LNSR | $82.29M | $6.70 | +0.45% | -45.13% | -3.18% | N/A | vs PMN |
| 5MNOV | $81.22M | $1.65 | -5.98% | +37.29% | -13.62% | -13.11% | vs PMN |
| 6NTRB | $81.20M | $6.68 | -10.58% | -4.74% | +6.67% | N/A | vs PMN |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 7 analysts
Average Price Target
$42.61
+362.6% upside
Low
$17.79
Current
$9.21
High
$98.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-1.37 | $-1.27 | $-1.16 | 2 |
| Quarter ending Dec 2026 | $-1.41 | $-1.32 | $-1.24 | 2 |
| Quarter ending Mar 2027 | $-1.11 | $-1.11 | $-1.11 | 1 |
| Quarter ending Jun 2027 | $-0.86 | $-0.86 | $-0.86 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-5.39 | $-5.10 | $-4.81 | 4 |
| FY 2027 | $-6.41 | $-3.81 | $-2.32 | 6 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $0.00 | $0.00 | $0.00 | 0 |
| FY 2027 | $0.00 | $0.00 | $0.00 | 0 |
